Welcome to our dedicated page for Mannkind news (Ticker: MNKD), a resource for investors and traders seeking the latest updates and insights on Mannkind stock.
MannKind Corporation (Nasdaq: MNKD) generates frequent news across product, clinical, regulatory, and corporate fronts as it advances therapies for cardiometabolic and orphan lung diseases. News coverage for MNKD often centers on its commercial products Afrezza, FUROSCIX, V-Go, and Tyvaso DPI–related collaborations, as well as updates on its inhaled and subcutaneous pipeline.
Investors and healthcare observers following MNKD news can expect announcements on U.S. Food and Drug Administration (FDA) milestones, including supplemental Biologics License Applications and supplemental New Drug Applications. Recent examples include FDA acceptance for review of an sBLA for Afrezza in children and adolescents with type 1 or type 2 diabetes, and acceptance of an sNDA for the FUROSCIX ReadyFlow Autoinjector for edema in adults with chronic heart failure or chronic kidney disease.
MannKind’s news flow also covers clinical trial progress and portfolio decisions in orphan lung diseases. The company has reported on initiation of nintedanib DPI (MNKD-201) studies for idiopathic pulmonary fibrosis, as well as the discontinuation of the Phase 3 ICoN-1 trial of nebulized clofazimine (MNKD-101) for refractory nontuberculous mycobacterial lung disease following a futility analysis. Updates on pre-clinical programs such as bumetanide DPI and MNKD-102 are also featured in its communications.
Corporate and financial news items include quarterly earnings results, revenue breakdowns across royalties, collaborations, and product sales, and strategic transactions. A notable example is MannKind’s acquisition of scPharmaceuticals, which brought FUROSCIX fully into its portfolio and expanded its presence in cardiometabolic care. The company also issues releases about investor conference presentations and community initiatives, such as the Centennial Al Mann Scholarship for students living with diabetes.
This news page aggregates these developments so readers can review regulatory decisions, trial outcomes, business combinations, and financial updates related to MannKind in one place.
MannKind Corporation (Nasdaq: MNKD) announced that CEO Michael Castagna will present at the BTIG Virtual Biotechnology Conference on August 11, 2020, at 2:00 pm ET. The live webcast will be accessible via the company's website, with a replay available for 14 days after the event. MannKind focuses on inhaled therapeutic products for diabetes and orphan lung diseases, with its flagship product, Afrezza® (inhaled insulin), being the only FDA-approved inhaled ultra-rapid-acting mealtime insulin available in the U.S.
MannKind Corporation (NASDAQ:MNKD) reported 2Q 2020 Afrezza net revenue of $7.0 million, up 15% from 2Q 2019, contributing to a total revenue of $15.1 million. For 1H 2020, net revenue was $15.0 million, a 35% increase year-over-year. Gross profit surged 90% to $3.3 million, boosting gross margin from 29% to 47%. The company reported a net loss of $10.3 million, an improvement from $12.4 million in 2Q 2019. Cash reserves stood at $63.2 million. New Chief Commercial Officer Alejandro Galindo joined to enhance growth.
MannKind Corporation (NASDAQ: MNKD) will announce its 2020 second quarter financial results and provide corporate updates during a conference call scheduled for August 5, 2020, at 5:00 PM ET. The call will feature CEO Michael Castagna and CFO Steven Binder. Interested parties can access the live call via the company's website, with a playback option available for 14 days post-call.
MannKind is focused on developing inhaled therapies for diabetes and orphan lung diseases, highlighting its commercial product, Afrezza®.
MannKind Corporation (NASDAQ: MNKD) has announced its participation in the Lytham Partners Virtual Investor Growth Conference, scheduled for June 24, 2020, at 12 pm ET (9 am PT). CEO Michael Castagna will present during a virtual fireside chat. A webcast of the presentation will be available on MannKind's investor website. Additionally, management will engage in one-on-one meetings with institutional investors on the same day. MannKind is known for developing inhaled therapeutic products, including the FDA-approved Afrezza®, an inhaled insulin product.
MannKind Corporation (Nasdaq: MNKD) announced the presentation of new clinical data for Afrezza® (insulin human) Inhalation Powder at the American Diabetes Association’s 80th Scientific Sessions on June 13, 2020. The study, led by Dr. Mark Kipnes, highlighted a significant 0.8% reduction in A1C levels in patients switching from injected insulin to Afrezza over 14 weeks. Participants reported improved diabetes quality of life and maintained glucose levels within the target range. Afrezza is the only inhaled ultra-rapid-acting mealtime insulin available in the U.S.
MannKind Corporation (NASDAQ:MNKD) reported a strong first quarter of 2020 with net revenue of $8.0 million from Afrezza, marking a 58% increase from Q1 2019. Gross profit rose significantly to 48%, up from 21% in the previous year. Total revenues reached $16.2 million, but collaboration revenue declined by $4.2 million due to the end of a research agreement. The net loss narrowed to $9.3 million, or $0.04 per share, reflecting reduced operating expenses. Cash reserves decreased to $39.2 million amid $11.2 million in operating cash use.
Summary not available.